The Dawn of a New Era in Medicine
Our population is increasing and living longer. Treatment demands are becoming more complex. The Association of American Medical Colleges predicts a shortfall of 100,000 physicians by 2030. AVRA is developing autonomous medical robotic systems that will help overcome these challenges.
The proprietary intelligent AVRA Instrument Guidance System (AIGS) will bring precise navigation and accurate targeting to robotic surgery resulting in a Surgeon interfaced autonomous platform.
AVRA’s imaging technology will be capable of high-resolution, multi-dimensional imaging with incorporated scanning and registration.
Inspired by biological neural networks, AVRA is working to incorporate artificial intelligence for enhanced diagnostic and therapeutic capabilities.
AVRA’s technology will be flexible and applicable across a diverse range of medical disciplines.
Patient Inspired Technology
AVRA is designing systems that will enable surgeons to simulate procedures for preoperative review prior to performing surgery. Patient specific mapping optimizes results both for the surgeon and the patient.
ACCELERATED BIOPSY RESULTS
To eliminate a primary source of patient anxiety, AVRA is using its technology to develop ways of sharply improving biopsy result waiting time from weeks or days to minutes.
Market Opportunity: Areas of Application
Beyond aesthetic medicine, AVRA’s platform independent design will allow expansion into a variety of medical fields, phase two being internal organ targeting. Procedures will include mapping, biopsy and tissue targeting. Where there is growing demand for procedures in soft tissue, neuro and spine surgery, AVRA will be there to meet it.
The Next Revolution
in Health Care
AVRA’s advanced technology incorporating human-machine interactions (HMI) will redefine the term ‘robotic’ by introducing autonomy to surgical robotics. AVRA’s imaging and instrument guidance technology will allow for unprecedented minimally invasive treatment with greater precision and accuracy.
AVRA Scientific Advisor
Investor, skillful leader, successful entrepreneur and ex-chairman of Oxford Health Plans.